Experiment 66907
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | BERGES,RR: KASSEN,A: SENGE,T:. (2000). TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA WITH BETA-SITOSTEROL: AN 18-MONTH FOLLOW-UP.. 85(7) |
| Amount utilized | |
| Compound isolated | |
| Disease | AT 18 MONTHS AFTER ENROLMENT IN A 6 MONTH MULTICENTRE DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL WITH BETA-SITOSTEROL PATIENTS WERE RE-EVALUATED USING THE MODIFIED BOYARSKY SCORE, THE INTERNATIONAL PROSTATE SYMPTOM SCORE AND QUALITY-OF- LIFE INDEX. THE MAXIMUM URINARY FLOW RATE AND POSTVOID RESIDUAL URINE VOLUME. IN THIS OPEN EXTENSION OF THE ORIGINAL TRIAL, PATIENTS WERE FREE TO CHOSE THEIR FURTHER TREATMENT FOR BPH. IN ALL, 117 PATIENTS (59%) WERE ELIGIBLE FOR ANALYSIS DURING THE FOLLOW-UP. OF THE FORMER BETA-SITOSTEROL GROUP, 38 PATIENTS WHO CONTINUED BETA-SITOSTEROL TREATMENT HAD STABLE VALUES FOR ALL OUTCOME VARIABLES BETWEEN THE END OF THE DOUBLE-BLIND SUTDY AND AFTER 18 MONTHS OF FOLLOW-UP. THE 41 PATIENTS CHOOSING NO FURTHER THERAPY HAD SLIGHTLY WORSE SYMPTOM SCORES AND PVR, BUT NO CHANGES IN QMAX OF THE FORMER PLACEBO GROUP. 27 PATIENTS WHO STARTED BETA-SITOSTEROL AFTER THE DOUBLE-BLIND TRIAL IMPROVED TO THE SAME EXTENT AS THE TREATED GROUP FOR ALL OUTCOME VARIABLES. THE 18 PATIENTS CHOOSING NO FURTHER THERAPY SHOWED NO SIGNS OF IMPROVEMENT. THE BENEFICIAL EFFECTS OF BETA-SITOSTEROL TREATMENT RECORDED IN THE 6-MONTH DOUBLE-BLIND TRIAL WERE MANITAINED FOR 18 MONTHS. FURTHER CLINICAL TRIALS SHOULD BE CONDUCTED TO CONFIRM THESE RESULTS BEFORE CONCLUDING THAT PHYTOTHERAPY WITH BETA-SITOSTEROL EFFECTIVE. |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | MALE |